Session Details

F069 Genodermatoses 101

Sat, Mar 9, 3:30 PM - 5:30 PM
Room 32B
2 CME Available Forum
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

Continued advances into the genetic basis of genodermatoses has led to an era of potential mechanism-based management of some of these challenging conditions. The overall goal of this session is to provide a framework for the practicing Dermatologist to assist in the evaluation a new patient with a potential genodermatosis and how/when to seek genetic confirmation. Faculty include pediatric and medical dermatologists as well as a dual dermatologist/geneticist who specialize in genodermatoses evaluation at the National Institutes of Health, Mayo clinic, Medical College of Wisconsin and Newcastle Hosp (UK).

LEARNING OBJECTIVES

1.

Categorize inherited skin conditions and the major biologic pathways responsible for their development

2.

Recognize key skin features that should prompt further evaluation for a genodermatosis

3.

Formulate a coordinated plan of care and referral for genetic evaluation when appropriate

SCHEDULE

11:30 PM

Introduction

Edward W Cowen, MD, FAAD

11:32 PM

Facial features of hereditary cancer predisposition

Neil Rajan, MBBS, PhD

12:00 AM

Update on genetic testing for the Dermatologist

Jennifer L. Hand, MD, FAAD

12:30 AM

Granulomas in Primary Immunodeficiency: What is the Role of Rubella?

Yvonne Chiu, MD, FAAD

1:00 AM

A VEXING problem: genetic diseases are not just for kids

Edward W Cowen, MD, FAAD

SPEAKERS

Yvonne Chiu, MD, FAAD

Yvonne Chiu, MD, FAAD

Edward W Cowen, MD, FAAD

Edward W Cowen, MD, FAAD

Jennifer L. Hand, MD, FAAD

Jennifer L. Hand, MD, FAAD

Neil Rajan, MBBS, PhD

Neil Rajan, MBBS, PhD

SPEAKER DISCLOSURES

Yvonne Chiu, MD, FAAD

No financial relationships exist with ineligible companies.

Edward W Cowen, MD, FAAD

No financial relationships exist with ineligible companies.

Jennifer L. Hand, MD, FAAD

UpToDate, Inc – Consultant(Patent royalties or other compensation for Intellectual Property Rights);

Neil Rajan, MBBS, PhD

No financial relationships exist with ineligible companies.